PubMed
Insulin-like growth factor-I and its binding proteins in sport and exercise medicine
Baxter RC. Endocr Rev. 2011
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 68% · Mixed 16% · Unfavorable overall 16%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 168 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 25–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 329 repeat reporters
Published sources linked on the IGF-1 LR3 and TB-500 Fragment wiki pages.
PubMed
Baxter RC. Endocr Rev. 2011
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025
PubMed
Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025
PubMed
Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026